SPY302.97-0.56 -0.18%
DIA254.35-1.42 -0.56%
IXIC9,368.99-43.37 -0.46%

BeiGene To Present Clinical, Non-Clinical Data On BRUKINSA, Tislelizumab At European Hematology Association Congress Jun. 11-14

BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today

Benzinga · 05/14/2020 13:15

BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that clinical and non-clinical data on BTK inhibitor BRUKINSA™ (zanubrutinib) and clinical data on anti-PD-1 antibody tislelizumab will be presented in an oral presentation and eight posters at the 25th European Hematology Association (EHA) Virtual Congress, taking place on June 11-14, 2020.

Oral Presentation:

Title:ASPEN: Results of a Phase 3 Randomized Trial Of Zanubrutinib Versus Ibrutinib for Patients with Waldenström Macroglobulinemia (WM)
Abstract #:S225
Session Title:Indolent and Mantle-Cell Non-Hodgkin Lymphoma – Clinical
Presenter:Meletios Dimopoulos, M.D., National and Kapodistrian University of Athens, Greece

Poster Presentations:

Title:Updated Results of the ASPEN Trial from a Cohort of Patients with MYD88 Wild-Type Waldenström Macroglobulinemia
Abstract #:EP1180
Session Title:Indolent and Mantle-Cell Non-Hodgkin Lymphoma – Clinical
Lead Author:Meletios Dimopoulos, M.D., National and Kapodistrian University of Athens, Greece

 

Title:Three-Year Follow-Up of Treatment-Naïve and Previously Treated Patients with Waldenström Macroglobulinemia (WM) Receiving Single Agent Zanubrutinib
Abstract #:EP1168
Session Title:Indolent and Mantle-Cell Non-Hodgkin Lymphoma – Clinical
Lead Author:Stephen Opat, MBBS, Monash University, Australia

 

Title:Phase 1/2 Study of Single-Agent Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma
Abstract #:EP1165
Session Title:Indolent and Mantle-Cell Non-Hodgkin Lymphoma – Clinical
Lead Author:Alessandra Tedeschi, M.D., Niguarda Cancer Center, Italy

 

Title:Tislelizumab (BGB-A317) for Relapsed/Refractory Extranodal NK/T-Cell Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study
Abstract #:EP1268
Session Title:Aggressive Non-Hodgkin Lymphoma – Clinical
Lead Author:Huiqiang Huang, M.D., Ph.D., Sun Yat-sen University Cancer Center, China

 

Title:Tislelizumab (BGB-A317) for Relapsed/Refractory Peripheral T-Cell Lymphomas: Safety and Efficacy Results from a Phase 2 Study
Abstract #:EP1235
Session Title:Aggressive Non-Hodgkin Lymphoma – Clinical
Lead Author:Pier Luigi Zinzani, M.D., Ph.D., University of Bologna, Italy

 

Title:Biomarker Identification in Relapsed/Refractory Non-Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma Treated with Zanubrutinib
Abstract #:EP1246
Session Title:Aggressive Non-Hodgkin Lymphoma – Clinical
Lead Author:Haiyan Yang, M.D., Zhejiang Cancer Hospital, China

 

Title:Zanubrutinib (BGB-3111) in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
Abstract #:EP1271
Session Title:Aggressive Non-Hodgkin Lymphoma – Clinical
Lead Author:Jianfeng Zhou, M.D., Tongji Medical College, China

 

Title:Outcomes of Relapsed/Refractory MCL Patients Treated with Zanubrutinib Monotherapy in the Second Line and in Later Lines: A Pooled Analysis from 2 Studies
Abstract #:EP1169
Session Title:Indolent and Mantle-Cell Non-Hodgkin Lymphoma – Clinical
Lead Author:Keshu Zhou, M.D., Henan Cancer Hospital, China